• Arun Dewan and Mujeeb Shoukat.
• Department of Medicine and Critical Care, Batra Hospital, New Delhi, India.
• Indian J Crit Care Med. 2014 Jul 1; 18 (7): 427-30.

AimThe aim was to evaluate the risk of nephrotoxicity with high-dose, extended-interval regimen of colistin administration in critical ill patients.Materials And MethodsThis prospective study was conducted on patients suffering from sepsis due to Gram-negative infection susceptible only to colistin. The dosing schedule for colistin was 9 million units stat followed by 4.5 million units at 12 hourly interval (adjusted as per body weight and renal functions). The serum creatinine and creatinine clearance were estimated at the start of therapy and daily during therapy.ResultsThirty-one patients suffering ventilator associated pneumonia (61.29%), blood stream infections (29.03%) and urinary tract infections (9.67%) due to Gram-negative multiple drug resistance organisms were assessed. Most commonly isolated organism were Acinetobacter baumannii (54.83%), Klebsiella pneumonia (16.12%) and Pseudomonas (29.03%). Five patients (16.12%) developed acute kidney injury within 4-5 days of start of therapy and returned to baseline after 6 days with no patient requiring renal replacement therapy or discontinuation of colistin.ConclusionOur study showed that high-dose, extended-interval colistin can be given to critically ill patients without any significant risk of nephrotoxicity.

1 keywords...

hide…